Alpha Cognition Inc. Common Stock (ACOG) — 分析摘要
Alpha Cognition Inc. Common Stock（ACOG）的市值为182.47百万美元，最近一年的营收同比增长了-89.8%。净利润率为-202.2%。当前市盈率为-7.3倍。
核心要点
- 营收同比变化-89.8%
- 净利润率-202.2%
- 市盈率-7.3倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，ACOG的营收增长为-89.8%，市盈率为-7.3倍。
Alpha Cognition Inc. Common Stock (ACOG)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -250.1% — 严重经营亏损
净利率为 -232.2% — 亏损超过收入（可能含一次性费用）
最新报表显示自由现金流为负。
毛利率为 92.2% — 请核实：除纯软件/IP外极少有企业维持 >90% 毛利率
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
71
总部
GRAPEVINE, TX
Exchange
XNAS
需要至少 3 年年度财务数据来评估竞争壁垒。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。